Datasheet

LIGHT Antibody [7B9H9]
CATALOG NUMBER: RF16062

Availability: In stock

$0.00
Product Price Options

* Required Fields

$0.00
Specifications
Properties
Additional Info
Background

Specifications

SPECIES REACTIVITY:Human
TESTED APPLICATIONS:ELISA, Flow, ICC, IF, IHC-P, WB
APPLICATIONS:LIGHT antibody can be used for detection of CD80 by Western blot at 0.5 - 1 μg/mL. LIGHT antibody can be used for immunohistochemistry starting at 2 - 5 μg/mL. For immunofluorescence start at 20 μg/mL.

Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples; Immunocytochemistry in human samples; Immunofluorescence in human samples and Flow Cytometry in mouse samples. All other applications and species not yet tested.
USER NOTE:Optimal dilutions for each application to be determined by the researcher.
POSITIVE CONTROL:1) Cat. No. 1331 - Human Lymphoma Tissue Lysate
PREDICTED MOLECULAR WEIGHT:Predicted: 26 kDa

IMMUNOGEN:LIGHT antibody was raised against the extracellular domain of human LIGHT.
HOST SPECIES:Mouse

Properties

PURIFICATION:LIGHT Antibody is supplied as protein A purified IgG2b.
PHYSICAL STATE:Liquid
BUFFER:LIGHT Antibody is supplied in PBS containing 0.02% sodium azide.
CONCENTRATION:1 mg/mL
STORAGE CONDITIONS:LIGHT antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
CLONALITY:Monoclonal
ISOTYPE:IgG2b
CONJUGATE:Unconjugated

Additional Info

ALTERNATE NAMES:LIGHT Antibody: TNFSF14, LTg, CD258, HVEML, HVEM ligand
ACCESSION NO.:NP_003798
PROTEIN GI NO.:25952144
OFFICIAL SYMBOL:TNFSF14
GENE ID:8740

Background

BACKGROUND:LIGHT Antibody: LIGHT, also known as Tumor Necrosis Factor Superfamily member 14 (TNFSF14), is a co-stimulatory molecule that can regulate T-cell activation (1) and has recently been identified as an immune checkpoint protein. LIGHT binds to two different receptors, Herpes Virus Entry Mediator (HVEM) and Lymphotoxin beta Receptor (LTβR). While LIGHT binding to HVEM delivers a co-stimulatory signal to T cells (1), LIGHT binding to LTβR is critical for the formation of lymphoid structures which can stimulate T cell infiltration and activation of a tumor microenvironment, leading to rapid T cell-mediated tissue destruction (2). It has been shown that targeted delivery of LIGHT to tumors, thereby causing the T cell infiltration of the tumor, can enhance the response of the PD-1/PD-L1 checkpoint blockade anti-cancer therapy (3), suggesting that LIGHT may become a potent tool in anti-cancer treatment.
REFERENCES: 1) Wang Y, Zhu M, Miller M, et al. Immunoregulation by tumor necrosis factor superfamily member LIGHT. Immunological Reviews 2009; 229:232–43.
2) Lee Y, Chin RK, Christiansen P, et al. Recruitment and activation of naive T cells in the islets by lymphotoxin beta receptor-dependent tertiary lymphoid structure. Immunity 2006; 25:499-509.
3) Tang H, Wang Y, Chlewicki LK, et al. Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-L1 blockade. Cancer Cell 2016; 29:285-296.

For Research Use Only